The largest life sciences association in the state recognized those driving discovery during its 32nd annual dinner meeting ...
After the rejection of Lykos Therapeutics’ MDMA-based PTSD treatment tempered excitement for psychedelic therapeutics, a ...
FDA's rejection of MDMA therapy for PTSD doesn't dampen hopes for other psychedelic treatments. Read more here.
Amid current economic uncertainties, investing in defensive stocks appears as your best bet for stability, especially if a ...
The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical company Johnson & Johnson created the spray from esketamine, a more ...
In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks after J&J secured FDA monotherapy approval for its esketamine nasal spray ...
The Food and Drug Administration recently expanded approval for Spravato, an antidepressant nasal spray used to treat depression.
A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...
The reference product for Awakn's NDA will be J&J's Spravato®, which is forecast to achieve US$1bn in sales in 2024. Subject to successful clinical trial outcomes and FDA approval, AWKN-002 could be ...
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of MDD in those who have not responded to at least two oral antidepressants. Hundreds of ...